The move is likely part of the company’s goal to reduce costs as it faces increased competition in the GLP-1 space.

Ron Lanton, partner, Lanton Law, warns that ongoing lawsuits targeting vaccine policy could create ripple effects across FDA ...

EMD Serono recently named Miguel Fernandez Alcalde as its new president. The new executive spoke with Pharmaceutical ...

The disease doesn’t have any FDA approved treatments, leaving families desperate for FDA to approve the treatment.

Why pharma and all stakeholders in the healthcare ecosystem should undertake a fundamental shift in how evidence to support ...

The collaboration will explore RNA-based small molecule drug candidates aimed at neurological conditions where existing ...

Rob Abbott, CEO, ISPOR, highlights how AI is streamlining research and improving patient care while stressing the importance of human oversight.

Recent advancements in COPD treatments are providing patients with potential new first-line treatments. Pharmaceutical ...

Ron Lanton, partner, Lanton Law, warns that recent changes to federal vaccine recommendations could trigger extensive litigation as insurers, providers, and patients face new access and coverage ...

The global biotherapeutics company announced that it will seek to streamline operations as part of a broader transformation ...

Novo Nordisk reduces Ozempic's price to $499/month for self-paying patients, enhancing access to essential diabetes treatment ...

NIH's new strategy emphasizes transparency, prioritizes urgent health needs, and shifts focus to domestic research and ...